Multi-Office Locke Lord Team Advises Imugene on Transaction Valued up to $227 Million From Precision BioSciences

A Locke Lord team led by Douglas Gray, Jeff Jefferson and Katie Morin (all of Providence) advised Imugene Ltd., an Australian company listed on the Australian stock exchange (IMU:AUX) that is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies seeking to activate the immune system of cancer patients to treat and eradicate tumors, on the acquisition. Imugene received a worldwide exclusive license to Precision BioSciences, Inc.’s allogeneic CD19 ‎CAR T-cell therapy program for oncology and a related manufacturing facility for total deal consideration valued up to $227 million.‎ The license grants Imugene the potential to start a registration-enabling clinical study in 2024 for patients with third and fourth-line diffuse large B cell lymphoma and other blood cancer indications. For more information, see the press release. Additional support was provided by Joseph Farside, Lori Basilico, Gene McDermott (all of Providence), Chris Flanagan, Ralph Loren (all of Boston), Stephen Murphy (Washington, D.C.), Jaremi Chilton (San Francisco), Geoff Polma (Dallas) and Julie Dziobak (Boston).
Posted on August 18, 2023